araag2/HINT huggingface dataset:
Clinical trial NCT00441298 (phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: tenofovir gel, placebo (universal hec placebo)
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18-40 years (inclusive)

          -  Able and willing to provide written informed consent to be screened for, and to enrol
             in, the study.

          -  Able and willing to provide adequate locator information for study retention purposes.

          -  Sexually active, defined as having had vaginal intercourse at least twice in the past
             30 days prior to screening.

          -  HIV negative on testing performed by study staff within 30 days of enrolment.

          -  Have a negative pregnancy test which was performed by study staff within 21 days of
             enrolment

          -  Agree to use a non-barrier form of contraceptive

          -  Agree to adhere to study visits and procedures

        Exclusion Criteria:

          -  History of adverse reaction to latex.

          -  Plans any of the following during the next 16 to 30 months (depending the anticipated
             date of study completion):

               -  To travel away from the study site for more than 30 consecutive days.

               -  To relocate away from the study site.

               -  To become pregnant

               -  To enrol in any other study of an investigational product or behaviour
                  modification related to HIV prevention.

          -  Has a creatinine clearance <50ml/min, as estimated using the method of Cockcroft and
             Gault(33).

          -  Has active Hepatitis B infection (since January 2009)

          -  Has a clinically apparent pelvic examination finding (observed by study staff)
             involving deep epithelial disruption. Otherwise eligible participants with pelvic
             examination findings involving deep epithelial disruption may proceed with enrolment
             after the findings have resolved and the inclusion/exclusion are met.

          -  Has in the past year participated in any research related to any vaginally applied
             product/s.

          -  Has current STI symptoms and/or other reproductive tract infection requiring
             treatment, as assessed by study staff. Otherwise eligible participants diagnosed
             during screening with infection(s) requiring treatment may be enrolled provided that
             treatment has commenced.

          -  Has any other condition that, based on the opinion of the Investigator or designee,
             would preclude provision of informed consent, make participation in the study unsafe,
             complicate interpretation of study outcome data, or otherwise interfere with achieving
             the study objectives.
Clinical trial NCT00631033 (phase 2, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: placebo, diazoxide, metformin + diazoxide
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  male

          -  age 25-50 years

          -  BMI 30-35 kg/m2

          -  stable body weight during 3 months before the start of the study

          -  glucose <= 6.0 mmol/L

          -  C-peptide >= 1.0 nmol/L

          -  HbA1c <= 6.0%

        Exclusion Criteria:

          -  comorbidity

          -  medication

          -  serum creatinine > 120 micromol/L

          -  liver enzymes > 2 times upper limits of normal

          -  gout

          -  alcohol use > 2 alcoholic drinks a day

          -  drug abuse

          -  cessation of smoking less than 6 months ago
Clinical trial NCT01794208 (phase 2, status: completed)
Conditions: infertility
ICD codes: N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8
Drugs: fsh-gex(tm), gonal-f(r)
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female patient for whom ICSI treatment is justified

          -  serum follicle-stimulating hormone concentration

          -  Anti-mullerian hormone concentration

          -  Antral follicle count

          -  Body mass index and body weight

          -  Presence of both ovaries

          -  Regular spontaneous cycles between 21 and 35 days in length

          -  Normal uterine cavity as assessed by transvaginal sonography at Screening

          -  Willing and able to comply with the protocol

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Patients who had more than two unsuccessful previous assisted reproduction technology
             cycles before inclusion into the study

          -  Previous poor responders

          -  Patients with previous hyperstimulation syndrome or cycle cancellation because of
             imminent hyperstimulation syndrome

          -  Patients with a history of or current polycystic ovarian morphology syndrome

          -  Patients with a history of or current endometriosis III or IV

          -  Presence of ovarian cyst at Screening

          -  Any contraindication to becoming pregnant

          -  History of ≥ 3 clinical or preclinical miscarriages

          -  abnormal cervical smear, Papanicolaou [PAP] score ≥ 3

          -  Any history of malignant cancer other than in situ breast or skin cancer requiring
             local excision

          -  Any endocrine abnormalities requiring treatment

          -  Any clinically significant systematic disease

          -  Any known infection with human immunodeficiency virus, hepatitis B or C

          -  History of thrombosis or other risk factors including any coagulation abnormality
             leading to an increased risk of clotting

          -  Family history of genetic risk factors concerning pregnancy or birth

          -  Use of concomitant medication, which in the opinion of the investigator might
             interfere with ICSI preparation procedures

          -  Active smoking

          -  Any active substance abuse of drugs, medications or alcohol within the last five years

          -  Patients in an institution by official or court order

          -  Patients who are unable or unwilling to provide informed consent

          -  Any participation in another clinical trial within the last 60 days before
             randomisation

          -  Previous FSH-GEX™ administration.

          -  Known hypersensitivity to any component of the investigational and non investigational
             products used in this study
Clinical trial NCT00368121 (phase 2, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: cetuximab +/- dexamethasone
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Reason stopped: 
    lack of recruitable patients
  
Eligibility criteria:

        Inclusion Criteria:

          -  Multiple myeloma diagnosed according to the Durie-criteria in stage II or III (Salmon
             and Durie)

          -  Measurable disease

          -  Refractory or relapsed disease after at least one line of treatment

          -  Male or female >= 18 years of age

          -  Life expectancy > 12 weeks

          -  ECOG performances status 0-2

          -  If of childbearing potential, willingness to use effective contraceptive method for
             the study duration and 6 months post-dosing.

          -  No surgery, radiotherapy or chemotherapy or any investigational agent within 30 days
             of study entry

          -  Signed written informed consent

        Exclusion Criteria:

          -  Asecretory multiple myeloma

          -  Patients eligible and willing to undergo high dose chemotherapy followed by autologous
             stem cell transplantation

          -  Prior allogeneic transplantation

          -  Prior antibody or EGFR-pathway targeting therapy

          -  Severe cardiovascular disease like functionally restricting heart rhythm disturbance
             or heart malformation or severe hypertension, or cardiac insufficiency > NYHA-II

          -  HIV Infection, Hepatitis B or C

          -  Brain disorders, psychiatric illness

          -  Insufficient bone marrow reserve (Leucocytes < 1500/µl; Thrombocytes < 50000/µl)

          -  Creatinine-Clearance < 30 ml/min or Crea > 3.0 mg/dl

          -  Bilirubin > 2 mg/dl; ASAT, ALAT > 100 U/l

          -  Pregnancy (absence confirmed by serum/urine beta-HCG) or breast-feeding

          -  FEV1 < 50% of the reference value

          -  Active secondary malignancy

          -  Legal incapacity or limited legal capacity

          -  Having participated in another clinical trial or any investigational agent in the
             preceding 30 days

          -  Known allergic/hypersensitivity reaction to any compounds of the treatment

          -  Other previous malignancy within 5 years, with exception of a history of a previous
             basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the patient to complete the study or sign meaningful informed consent

          -  Known drug abuse/alcohol abuse
Clinical trial NCT01230619 (phase 2, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: rv568, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is healthy

          -  History of seasonal allergic rhinitis

          -  Male aged between 18 and 55 years

          -  Body weight >/= 50 kg with BMI in range 19 - 29 kg/m2 (inclusive)

          -  Exhibits a moderate response to 4 hour exposure to grass pollen in the challenge
             chamber with a total nasal symptom score (TNSS) of >/= 6

          -  Positive skin prick test (wheal >/= 4 mm) for grass pollen

          -  Positive total IgE result (RAST class >/= 2) for grass pollen

          -  Current non-smoker who has not used tobacco in the past 6 months with a pack history
             of </= 10 pack years

          -  Baseline FEV1 >/= 80% and FEV1/FVC >/= 70% of predicted values

          -  No conditions or factors that may preclude subjects ability to remain in the challenge
             chamber for a period of 6 hours

          -  capable of giving informed consent and is compliant with protocol requirements

          -  available to complete all study measurements

        Exclusion Criteria:

          -  structural nasal abnormalities or nasal polyps, history of frequent nosebleeds, recent
             nasal surgery or recent (within 3 weeks) or ongoing upper respiratory tract infection

          -  history of drug allergy

          -  participation in another clinical trial or has participated in a study using an NCE
             within the previous 3 months, or any clinical study within 1 month

          -  taking regular (or a course of) medication whether prescribed or not, including
             steroids, vitamins, macrolides, anti-fungal agents and herbal remedies. Paracetamol
             (</= 2g / day) and occasional short acting beta agonists are permitted

          -  use of oral, injectable or dermal steroids within 5 weeks or intranasal and/or inhaled
             steroids within 1 week of the screening visit

          -  past or present disease, which as judged by the investigator, may affect the outcome
             of the study

          -  regular consumption of > 21 units alcohol per week

          -  infected with Hepatitis B, Hepatitis C, or HIV virus

          -  current or chronic history of liver disease, or known hepatic or biliary abnormalities

          -  positive test for drugs of abuse or alcohol at screening

          -  previously known allergy to any of the active or inactive ingredients in the study
             medication

          -  mentally or legally incapacitated

          -  any other reason that the investigator considers makes the subject unsuitable to
             participate
Clinical trial NCT00217555 (phase 2, status: completed)
Conditions: fallopian tube cancer, ovarian cancer, peritoneal cavity cancer
ICD codes: C57.00, C57.01, C57.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818
Drugs: gemcitabine hydrochloride, topotecan hydrochloride
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of ovarian, fallopian tube, or primary peritoneal cavity cancer

          -  Recurrent or persistent platinum-refractory disease, as defined by 1 of the following:

               -  Progressive disease while on a platinum compound

               -  Persistent clinically measurable disease with best response as stable disease at
                  the completion of ≥ 6 courses of therapy

               -  Recurrent disease within 6 months after completion of therapy

          -  Measurable or evaluable disease

               -  Evaluable disease, defined as CA 125 ≥ 100 U/mL (confirmed by 2 blood tests)

               -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
                  conventional techniques, including palpation, plain x-ray, CT scan, or MRI, OR ≥
                  10 mm by spiral CT scan

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  GOG 0-3

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  SGOT ≤ 2.5 times ULN

          -  Alkaline phosphatase ≤ 2.5 times ULN

        Renal

          -  Creatinine ≤ 1.5 times ULN

          -  Creatinine clearance > 50 mL/min

        Other

          -  No clinically significant infection

          -  No other severe medical condition that would preclude study treatment

          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or
             carcinoma in situ of the cervix or breast

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  See Disease Characteristics

          -  Prior gemcitabine or topotecan allowed provided disease is not refractory to either
             drug

          -  At least 3 weeks since prior chemotherapy and recovered

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  At least 3 weeks since prior radiotherapy and recovered

        Surgery

          -  Recovered from recent prior surgery
Clinical trial NCT00558207 (phase 2, status: completed)
Conditions: pancreatic neoplasms
ICD codes: C25.3
Drugs: arq 197, gemcitabine
SMILES: O=C1NC(=O)[C@H]([C@@H]1C1=CNC2=CC=CC=C12)C1=CN2CCCC3=C2C1=CC=C3, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Able to provide signed and dated informed consent prior to study-specific screening
             procedures

          2. ≥ 18 years old

          3. Histologically or cytologically confirmed locally advanced or metastatic unresectable
             pancreatic adenocarcinoma

          4. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)

          5. Karnofsky performance status (KPS) ≥ 70%

          6. Male or female patients of child-producing potential must agree to use double barrier
             contraception, oral contraceptives or avoidance of pregnancy measures during the study
             and for 90 days after the last day of treatment

          7. Females of childbearing potential must have a negative serum pregnancy test

          8. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of
             normal (ULN) or ≤ 5 × ULN with metastatic liver disease

          9. Hemoglobin ≥ 10 g/dl

         10. Total bilirubin ≤ 1.5 × ULN

         11. Serum creatinine ≤ 1.5 x ULN

         12. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L

         13. Platelets ≥ 100 x 10^9/L

        Exclusion Criteria:

          1. Received any prior therapy for the treatment of their pancreatic malignancy (including
             chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or
             irradiation, whether conventional or investigational)

          2. Central nervous system metastases

          3. Pregnant or breastfeeding

          4. Significant gastrointestinal disorder, in the opinion of the Principal Investigator
             (e.g. Crohn's disease, ulcerative colitis, extensive gastric resection)

          5. Unable or unwilling to swallow ARQ 197 capsules twice daily

          6. Other cancer within the last five years, with the exception of adequately treated
             cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell
             carcinoma of the skin

          7. Significant co-morbid conditions that in the opinion of the Investigator would impair
             study participation

          8. Known human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection
Clinical trial NCT00245765 (phase 2, status: completed)
Conditions: chronic plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: certolizumab pegol
SMILES: OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult men and women > 18 years

          -  Subjects with chronic plaque psoriasis stable for at least 3 months and moderate to
             severe for at least 6 months

          -  Subjects with Psoriasis Area and Severity Index (PASI) ≥ 12 and Body Surface Area
             (BSA) ≥ 10 %

          -  Subjects were candidates for systemic psoriasis therapy and/or phototherapy and/or
             photochemotherapy

        Exclusion Criteria:

          -  Subjects with an erythrodermic, guttate, palmar or plantar, generalized pustular form
             of psoriasis

          -  A history of chronic infection, recent serious or life-threatening infection (within
             six months, including herpes zoster), or any current sign or symptom that may indicate
             an infection (e.g. fever, cough);

          -  White blood cell counts less than 4000/mm^3 or more than 20000/mm^3

          -  Suspected or diagnosed demyelinating disease of the central nervous system (e.g.
             multiple sclerosis or optic neuritis)

          -  Systemic Lupus

          -  Non respect of adequate wash out periods for treatments that might have an impact on
             the disease

          -  Any associated disease that could be impacted by the study treatment intake

          -  Any other condition, which in the Investigator's judgment would make the subject
             unsuitable for inclusion in the study
Clinical trial NCT00363779 (phase 2, status: terminated)
Conditions: large granular lymphocytic leukemia, lgl leukemia
ICD codes: A87.2, K52.832, D72.111, C91.11, C91.12, C91.10, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cyclosporine
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Reason stopped: 
    study terminated due to low accrual and the investigator left the nih.
  
Eligibility criteria:

        -  INCLUSION CRITERIA:

               1. All patients must have a histologic or cytologic diagnosis of T-cell LGL leukemia
                  as determined by the Laboratory of Pathology or Hematology at the Clinical
                  Center, National Institutes of Health

               2. All patients must have hemocytopenias such as granulocyte count less than
                  1,200/ul, platelet count less than 100,000/ul or hemoglobin less than 10 g/dl, or
                  require hematopoietic support (transfusion or colony stimulating factors) to
                  maintain counts at these or higher levels.

               3. Patients must have measurable or evaluable disease

               4. Patients must have a creatinine of less than 2.0 mg/dl.

               5. Omission of cytotoxic chemotherapy for 3 weeks prior to entry into the trial is
                  required. However, patients receiving stable corticosteroids will be eligible.

               6. Age greater than 18 years

               7. Karnofsky performance greater than 70%

               8. Patients must have a life expectancy of greater than 3 months.

               9. Patients must be able to understand and sign an Informed Consent form.

              10. All female patients must use adequate contraception during participation in this
                  trial and for three months after completing therapy.

        EXCLUSION CRITERIA:

          1. Patients with uncontrolled hypertension

          2. Pregnant and nursing patients are not eligible for the study as CSA crosses the
             placenta. Based on clinical use, premature births and low birth weight were
             consistently observed. Breast-feeding is contraindicated because CSA enters the blood
             milk and may possibly be administered to the child.

          3. Underlying immunodeficiency state including human immunodeficiency virus (HIV)
             seropositivity.

          4. Positive for antibodies to hepatitis C or positive for hepatitis B surface antigen,

          5. Patients with serious intercurrent illnesses, concurrent hepatic, renal, cardiac,
             neurologic, pulmonary, infectious or metabolic disease of such severity that it would
             preclude the patients' ability to tolerate cyclosporine.

          6. Patients who received cyclosporine for LGL leukemia previously and failed to respond.
Clinical trial NCT00491686 (phase 2, status: completed)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: azd6765
SMILES: N[C@@H](CC1=CC=CC=N1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Depression

          -  Inadequate response to an adequate course of antidepressants

        Exclusion Criteria:

          -  Psychiatric disorder other than depression

          -  Pregnancy or lactation

          -  Current diagnosis of cancer